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Abstract
Traumatic injury to peripheral nerves results in the loss of neural functions. Recovery by regeneration depends on
the cellular and molecular events of Wallerian degeneration that injury induces distal to the lesion site, the domain
through which severed axons regenerate back to their target tissues. Innate-immunity is central to Wallerian
degeneration since innate-immune cells, functions and molecules that are produced by immune and non-immune
cells are involved. The innate-immune response helps to turn the peripheral nerve tissue into an environment that
supports regeneration by removing inhibitory myelin and by upregulating neurotrophic properties. The
characteristics of an efficient innate-immune response are rapid onset and conclusion, and the orchestrated
interplay between Schwann cells, fibroblasts, macrophages, endothelial cells, and molecules they produce.
Wallerian degeneration serves as a prelude for successful repair when these requirements are met. In contrast,
functional recovery is poor when injury fails to produce the efficient innate-immune response of Wallerian
degeneration.
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Introduction
Traumatic injury to nerves in the PNS (peripheral ner-
vous system) results in the loss of neural functions.
Repair is achieved through regeneration of severed
axons and reinnervation of target tissues. Successful
functional recovery depends on the ensemble of cellular
and molecular events that develop distal to lesion sites
all the way towards denervated target tissues. Those
represent the PNS response to traumatic nerve injury
and are termed collectively Wallerian degeneration after
Waller [1].
Numerous studies have been carried out since Waller
first documented his findings. They provide essential,
yet incomplete understanding of the mechanisms that
control Wallerian degeneration and how those may be
influenced to provide grounds for best functional recov-
ery. Wallerian degeneration has been reviewed in recent
years; e.g. [2-6] and additional publications that are
cited throughout the text.
This review focuses on the cellular and molecular
events that highlight Wallerian degeneration as the
innate-immune response of the PNS to traumatic nerve
injury (e.g. recruitment of macrophages, phagocytosis of
degenerated myelin, and production of cytokines and
chemokines). Special attention is given to the orchestra-
tion of these events with respect to their timing and
magnitude, and to the identity of the cells that produce
them. Timing differs between species (see below).
Therefore, it is important to consider which animal
model was used when analyzing and integrating data.
Those that will be most discussed here are wild-type
and mutant Wld
s mice, which respectively display “nor-
mal Wallerian degeneration” and delayed “slow Waller-
ian degeneration”. Further, the coordination between
cellular and molecular events of Wallerian degeneration
that follow crush injuries may differ from those that fol-
low cut injuries. The connective tissue sheath of periph-
eral nerves does not tear apart after crush but does so
after complete transection. Therefore, it is difficult to
ascertain that all axons are severed by crushing. Addi-
tionally, severed axons regenerate readily after crush but
not after transection. Consequently, the cellular and
molecular events of Wallerian degeneration may be
altered by the regenerating axons (see below). Therefore,
the nature of the injury must also be considered.
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describe events that follow traumatic injury to CNS
(central nervous system) axons (e.g. spinal cord injury).
However, Wallerian degeneration in PNS and CNS dif-
fer with respect to the types of cells involved (e.g.
Schwann cells and macrophages in PNS versus oligo-
dendrocytes and microglia in CNS) and outcome (e.g.
removal of degenerated myelin during PNS Wallerian
degeneration but not during CNS Wallerian degenera-
tion). Therefore, it may be useful to use the terms PNS
Wallerian degeneration and CNS Wallerian degenera-
tion to avoid confusion when both are discussed.
Further, the term Wallerian degeneration is sometimes
used to define events that develop during PNS neuropa-
thies without trauma (e.g. inherited demyelinating dis-
eases). However, those differ from injury-induced
Wallerian degeneration, which may lead to confusion.
The term Wallerian degeneration that is used in this
review refers to injury-induced PNS Wallerian degenera-
tion unless otherwise specified.
Traumatic injury to peripheral nerves, Wallerian
degeneration and functional recovery
Nerve bundles in the PNS are mainly composed of axons,
Schwann cells that enwrap those axons and further form
myelin sheaths around many, fibroblasts that are scattered
between nerve fibers, and vasculature that nourishes the
PNS tissue (Figure 1A and 2A). Traumatic injury to PNS
nerves produces abrupt tissue damage at the lesion site
where physical impact occurred (Figure 1B). Then, nerve
stumps that are located distal to lesion sites undergo the
cellular changes that characterize Wallerian degeneration
though they did not encounter the physical trauma
directly. Amongst others, axons break-down, Schwann
cells reject the myelin portion of their membranes, and
bone-marrow derived macrophages are recruited and
activated along with resident Schwann cells to remove
degenerated axons and myelin (Figures 1C, D & 1E and
Figure 2B).
Lesions may be restricted in length; e.g. less than five
millimeters in length, depending on how trauma is
inflicted. On the other hand, distal nerve segments that
undergo Wallerian degeneration and extend all the way
towards their target tissues may range between several
millimeters to many centimeters depending on species
(e.g. mice versus humans) and site of trauma (e.g. near
versus distant from innervated targets). When trauma
produces complete transection of the PNS nerves, lesion
sites include the gaps that are formed between proximal
and distal nerve stumps.
Functional recovery depends on successful regenera-
tion of the severed axons throughout distal nerve seg-
ments that undergo Wallerian degeneration. The most
important determinant for good functional recovery in
humans is prompt regeneration of the severed axons
[7-10]. Notably, repair is often less successful in humans
than it is in mice and rats. This discrepancy has been
attributed to the delayed onset of axon destruction, the
longer nerve segments that need to be cleared of degen-
erated myelin, and the longer distances that regenerating
axons need to grow to reach their target tissues in
humans. It is thought, therefore, that speeding Wallerian
degeneration may improve functional recovery.
Axon destruction and myelin disintegration
Species, axon diameter and length of the distal segment
determine how fast axons break-down during normal
Wallerian degeneration [11-13]. Fragmentation of axons
is first detected by light microscopy 36 to 44 hours after
nerve transection in mice and rats (Figure 1C), but only
after about one week in baboons. Then, axon destruction
may advance anterogradely at velocities ranging from
about 10 to 24 mm/hour. However, freeze fracture stu-
dies reveal changes in the distribution of intramembra-
nous particles in axons already 24 hours after the injury,
and in Schwann cells that enwrap those axons even ear-
lier - after 12 hours [14]. Disintegration of the myelin
sheath, and Schwann cell proliferation and rearrange-
ment into Bünger bands begin 2 days after injury [15].
The break-down of axons and myelin, along with other
features of PNS Wallerian degeneration (see below), is
delayed dramatically by 2 to 3 weeks in mutant Wld
s
mice (formerly named Ola mice) [12,16,17]. Therefore,
Wallerian degeneration in wild-type mice is defined here
“normal” and in Wld
s mice “slow”.
The molecular mechanisms that link between nerve
injury at lesion sites and the destruction of axons during
normal Wallerian degeneration have not been fully clari-
fied; discussed in detail in [3,5,18]. The finding of the aber-
rant molecule that is composed of the N-terminal 70
amino acids of multiubiquitination factor Ube4b fused to
NAD
+ synthesizing enzyme Nmnat1 in Wld
s mice led to
the notion that isoform(s) of Nmnat, which are produced
in neuronal cell bodies and transported anterogradely,
protect axons by inhibiting a self-destructing mechanism
[19-23]. In this context, depletion of Nmnat in axons con-
sequent to cutting off supply from the cell body, as after
nerve injury or knocking-out Nmnat, promotes axon
destruction, and conversely, overexpression provides neu-
roprotection. It is further proposed that Nmnat dysfunc-
tion may underlie neuropathies that are not triggered by
trauma, and that Nmnat-dependent signaling may be
targeted to promote neuroprotection. It is unclear which
product(s) of the Nmnat signaling cascade confer neuro-
protection directly, and what is the nature of the self-
destructing mechanism that Nmnat signaling inhibits.
The molecular mechanisms that link between nerve
injury at lesion sites and myelin disintegration further
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Page 2 of 14Figure 1 Intact and injured PNS nerves. A schematic representation of some of the cellular characteristics of (A) intact and (B through E)
injured PNS nerves that undergo normal Wallerian degeneration. (A) Intact myelinating Schwann cells enwrap an intact axon and fibroblasts are
scattered between nerve fibers. (B) Traumatic injury produces immediate tissue damage at the lesion site (marked by a circle), a gap (rectangle)
may be formed between the proximal and distal nerve stumps, and Galectin-3/MAC-2
+ macrophages accumulate at the lesion site within 24
hours after the injury. (C) Destruction of axons is detected during normal Wallerian degeneration 36 hours after the injury. (D) Recruitment of
Galectin-3/MAC-2
+ macrophages, myelin disintegration, and Galectin-3/MAC-2 expression by Schwann cells begin 48 to 72 hours after injury
during normal Wallerian degeneration. (E) Galectin-3/MAC-2
+ macrophages and Schwann cells scavenge degenerated myelin during normal
Wallerian degeneration, and Schwann cells further proliferate and form Bünger bands.
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not been entirely elucidated. However, the rapid and
transient activation of the Erb2 receptor in Schwann
cells by axon-derived neuregulin(s), which is detected 1
hour after the injury, may be involved [24]. It is unclear
how injury initiates neuregulin-Erb signaling, how neur-
egulin-Erb signaling propagates anterogradely, and how,
if at all, do Nmnat and neuregulin-Erb signaling cas-
cades relate one to the other. Notably, neuregulin-Erb
interactions may regulate both myelination and demyeli-
nation [25-31]. It has been suggested that BACE1 (b-
amyloid precursor protein cleaving enzyme 1), which
also cleaves neuregulin, regulates myelination and
remyelination [32-34]. Further, BACE1 does not affect
myelin disintegration but impedes clearance of degener-
ated myelin during Wallerian degeneration as BACE1
knock-out mice display faster clearance of myelin
whereas time to onset of myelin and axon disintegration
are not altered from normal [35].
Degenerated myelin is harmful
Removal of degenerated myelin is critical for repair since
PNS myelin contains molecules that inhibit regeneration
of severed axons (e.g. MAG; myelin associated glycopro-
tein) [36-40]. Indeed, clearance of myelin, axon regenera-
tion, and functional recovery are delayed considerably in
Wld
s mice compared to those in wild-type mice [41-43].
Regeneration of severed axons in Wld
s mice is improved
after knocking-out MAG even though myelin removal is
still slow [40]. In accord, PNS myelin and MAG inhibit
regeneration in-vitro [37-39]. The in-vitro inhibition of
axon growth may not be detected depending on neuron
identity (e.g. neonate versus adult) and whether adhesion
or growth factors are present. These features may explain
a report that PNS myelin is not inhibitory [44]. Further,
contradictory results on CNS myelin associated inhibitors
(e.g. Nogo, MAG and OMgp; oligodendrocyte myelin
associated glycoprotein) have also been reported and
further been explained through differences in experimen-
tal designs [45,46]. Nonetheless, most evidence indicates
that myelin as whole structure (i.e. specialized membra-
nous extensions of Schwann cells in PNS and oligoden-
drocytes in CNS) inhibits the regeneration of adult PNS
and CNS axons; e.g. [47,48] and recent reviews [49-51].
The rapid clearance of degenerated myelin can also avert
damage from intact axons and myelin after partial injury
to PNS nerves where some but not all axons are axoto-
mized by the impact (Figure 1; imagine that axon A is situ-
ated next to axon E). Here, degenerated myelin may
activate the complement system to produce membrane
attack complexes which, in turn, inflict damage to remain-
ing nearby intact axons and myelin [52-54]. The rapid
clearance of degenerated myelin may impede the produc-
tion of membrane attack complexes and the damage they
cause. Of note, complement activation has also beneficial
effects since it advances macrophage recruitment and pha-
gocytosis of degenerated myelin (see below).
Schwann cells and macrophages are activated to
scavenge degenerated myelin
Resident Schwann cells and recruited macrophages clear
degenerated myelin in wild-type mice during normal
Figure 2 Intact axon, normal Wallerian degeneration, and kinetics of myelin clearance and Galectin-3/MAC-2 expression during
normal Wallerian degeneration. (A) A Schwann cell that is surrounded by basal lamina (arrow heads) forms a myelin sheath around an intact
axon; Bar 1 μm. (B) Axons are not detected 7 days after the injury, and Schwann cells (S) and a macrophage (m), which are situated within basal
lamina sheaths (dark arrow heads), contain myelin fragments and lipid droplets in their cytoplasm (white arrow heads) (after [16]); Bar 2 μm. (C)
Time course of myelin phagocytosis and degradation (Po) and Galectin-3/MAC-2 protein (Gal-3) production. Phagocytosis and degradation of
myelin result in the reduction of tissue content of the myelin specific molecule Po. Nerve segments located 5 millimeters distal to lesion sites
were removed from wild-type mice at the indicated times and used to determine tissue levels of Po and Gal-3 by ELISA. Those are presented as
percentage of their maximal values that are defined 100% (after [60]).
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vivo experimental manipulations of macrophage deple-
tion [57], which test clearance by Schwann cells without
macrophages, and freeze-damaging nerves [16], which
test clearance by recruited macrophages without
Schwann cells, further indicate that each cell type can
remove myelin in-vivo without the other. Schwann cells
[16,58] and macrophages [59] can each scavenge myelin
in-vitro as well.
The time course of myelin clearance was studied in
detail in wild-type mice during normal Wallerian degen-
eration following a cut injury; [60] and Figure 2C. It
begins 3 to 4 days after the injury and is completed after
12 to 14 days. Myelin destruction and removal are
delayed considerably during slow Wallerian degeneration
in Wld
s mice, as are axon destruction and macrophage
recruitment [16,17,42,60].
The time course of myelin removal is determined by the
kinetics of macrophage recruitment and the kinetics of the
activation of macrophages and Schwann cells to scavenge
degenerated myelin. Bone-marrow derived macrophages,
which are scarce in intact PNS nerves of normal and Wld
s
mice, accumulate at injury sites within hours after the
trauma through ruptured vasculature and secondary to the
rapid local production of cytokines and chemokines that
attract macrophages to these sites; [61-63] and Figure 1B.
The recruitment of macrophages during normal Wallerian
degeneration is by diapedesis through vasculature that is
structurally intact since it does not encounter physical
trauma directly. It begins 2 to 3 days after a cut injury and
it peaks at about 7 days [16,42,43,64,65]. In contrast,
macrophage recruitment is delayed considerably in Wld
s
mice during slow Wallerian degeneration. However, Wld
s
macrophages invade freeze-damaged Wld
s PNS nerves
promptly [16], suggesting that Wld
s macrophages can
respond to chemotactic signals that freeze-damaged nerves
produce, and further, that chemotactic signals are not
upregulated during slow Wallerian degeneration, as indeed
it was later shown [61] (see also below). The exact molecu-
lar mechanisms that link between the physical impact at
lesion sites and macrophage recruitment to distal nerve
segments during normal Wallerian degeneration are not
fully understood. Yet, cytokines and chemokines that
attract macrophages [61-63,66-68], MMPs (matrix metal-
loproteinases) [69-72], and complement [73-75] play roles
(see below).
CR3 (complement receptor-3) and SRA (scavenger
receptor-AI/II) have long been suggested to mediate pha-
gocytosis of degenerated myelin by macrophages in con-
text of trauma [59,73,76-80]. Recently, a role for FcgR
(Fcg receptor) and endogenous anti-myelin Abs has also
been suggested [81]. Further, phagocytosis is augmented
2 folds and more after degenerated myelin activates the
complement system to produce the complement protein
C3bi which opsonizes myelin. Consequently, CR3 may
bind to C3bi-opsonized myelin through C3bi and to
unopsonized myelin directly. CR3 functions, therefore,
both as a C3bi-opsonic and a non-opsonic receptor. SRA
functions as a non-opsonic receptor that binds unopso-
nized myelin directly. However, SRA may also assist in
the phagocytosis of C3bi-opsonized myelin since C3bi-
opsonization does not block SRA binding sites on myelin.
Altogether, CR3 contributes 2 to 3 folds more to myelin
phagocytosis than SRA. Apart from complement, inflam-
matory cytokines TNFa (tumor necrosis factor-a) and IL
(interleukin)-1b, which are produced during normal
Wallerian degeneration, but not during slow Wallerian
degeneration, also upregulate myelin phagocytosis by
macrophages [63]. Of note, CR3 and SRA are similarly
involved in myelin phagocytosis by CNS microglia.
Galectin-3/MAC-2 activates macrophages and Schwann
cells to scavenge degenerated myelin (Appendix 1). There-
fore, the time-course of Galectin-3/MAC-2 expression
may reflect the kinetics of phagocytosis activation during
Wallerian degeneration. Expression was studied in detail
i nt h es a m ew i l d - t y p ea n dW l d
s mice in which myelin
clearance and macrophage recruitment were examined;
[16,60] and Figure 2C. Intact wild-type PNS nerves do not
express detectable levels of Galectin-3/MAC-2. Expression
is rapidly and transiently upregulated during normal
Wallerian degeneration following cut injuries. Galectin-3/
MAC-2 is first detected in Schwann cells 48 to 72 hours
after injury, and then also in recruited macrophages. Nota-
bly, the onset of Galectin-3/MAC-2 expression precedes
myelin clearance, expression is highest during the time
period at which most of the degenerated myelin is
removed, and expression is down-regulated after myelin
clearance is completed. Galectin-3/MAC-2 is not
expressed in intact Wld
s PNS nerves or during slow Wal-
lerian degeneration, but is expressed in injured Wld
s PNS
nerves at lesion sites where macrophages accumulate and
phagocytose degenerated myelin. Thus, the occurrence
and timing of Galectin-3/MAC-2 expression in cells that
scavenge myelin are in accord with those of myelin clear-
ance. The cytokine GM-CSF (granulocyte colony stimulat-
ing factor), which is produced during normal Wallerian
degeneration, but dramatically less during slow Wallerian
degeneration, upregulates the expression of Galectin-3/
MAC-2 in macrophages, Schwann cells and the entire
PNS nerve tissue [60,82].
Galectin-3/MAC-2 expression and the occurrence of
myelin phagocytosis correlate in the CNS as they do in
the PNS. CNS microglia that fail to phagocytose degen-
erated myelin in-vivo during CNS Wallerian degenera-
tion do not express Galectin-3/MAC-2 [83]. In contrast,
microglia that phagocytose degenerated myelin in-vivo
during experimental allergic encephalomyelitis [84] and
in-vitro [85] express Galectin-3/MAC-2.
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PNS injury induces immune and non-immune cells to
produce cytokines (Appendix 2) at and distal to lesion
sites. Consequently, a cytokine network is set in motion
in wild-type mice during normal Wallerian degeneration
(Figure 3A and 4A). Cytokine mRNAs expression and
detailed kinetic studies of cytokine protein production
and secretion, along with the identification of the produ-
cing cells, were carried out after complete nerve transec-
tion in the same wild-type and Wld
s mice in which
myelin clearance, macrophage recruitment and Galectin-
3/MAC-2 expression were studied; see above and
[60,63,82,86,87]. Findings suggest that timing and magni-
tude of cytokine production depend on the identity and
spatial distribution in the PNS tissue of the non-neuronal
cells that produce cytokines, and the timing of macro-
phage recruitment.
Resident Schwann cells normally express the mRNAs of
the inflammatory cytokines TNFa and IL-1a,a n dt h e
TNFa protein. Schwann cells that form close contacts
with axons are the first amongst non-neuronal cells to
respond to axotomy by rapidly upregulating the expression
and production of TNFa and IL-1a mRNAs and proteins;
the secretion of TNFa and IL-1a proteins is detected
within 5 to 6 hours after injury. Schwann cells also express
and produce IL-1b mRNA and protein, the secretion of
which is detected between 5 to 10 hours after injury. This
delayed expression and production of IL-b may be induced
by the Schwann cell-derived TNFa, thus through an auto-
crine effect. Concomitantly, Schwann cell-derived TNFa
and IL-1a induce nearby resident fibroblasts to express
and further produce the mRNAs and proteins of cytokines
IL-6 and GM-CSF, the secretion of which is detected
within 2 to 5 hours after the injury. Of note, the highest
levels of TNFa and IL-1b protein secretion are detected 1
day after the injury, thus before macrophage recruitment
begins. IL-6 protein secretion is biphasic; the first phase
peaks at day 2 just before macrophage recruitment begins,
and the second peaks at day 7.
Inflammatory cytokines and chemokines (see below)
advance the recruitment of blood-borne macrophages.
Recruitment begins 2 to 3 days after the injury and peaks
at about 7 days. The production and secretion of TNFa
and IL1-b proteins is reduced while macrophages increase
in number, suggesting that recruited macrophages pro-
duce little TNFa and IL1-b. Recruited macrophages pro-
duce and secrete IL-6 and IL-10 proteins, but little if any
GM-CSF protein. The second phase of IL-6 production
develops and then peaks at day 7 after the injury concomi-
tant with the timing and magnitude of macrophage
recruitment. The production and secretion of the anti-
inflammatory cytokine IL-10 protein is induced in resident
fibroblasts within 5 hours after injury, but levels are low
and ineffective since nerve-resident fibroblasts are poor
producers of IL-10, and Schwann cells do not produce IL-
10. In contrast, recruited macrophages produce and
secrete IL-10 protein effectively; levels increase and then
peak at day 7 concomitant with the timing and magnitude
of macrophage recruitment. Then, IL-10 gradually down-
regulates the production of cytokines, bringing the cyto-
kine network of normal Wallerian degeneration to conclu-
sion 2 to 3 weeks after injury, which is after degenerated
myelin has already been cleared. Of note, the production
and secretion of GM-CSF protein is attenuated but not
reduced during the second stage of normal Wallerian
degeneration. However, at that time, a GM-CSF binding
molecule that inhibits GM-CSF activity is produced [88].
Cytokines mRNAs expression was studied after crush
injuries that are followed by axonal regeneration 4 to 7
days after the injury. In one study [72], the induction of
TNFa and anti-inflammatory TGF-b1m R N A sw a s
biphasic; the first peaked at day 1 and the second at day 7
after crush. In other studies (summarized in [2]), a single
phase of induction that peaked at day 1 after crush was
detected for TNFa,I L - 1 b,I L - 6a n dI L - 1 0m R N A s .E v i -
dently, discrepancies exist between the kinetics of cyto-
kine proteins production and secretion following cut
injuries and the kinetics of cytokine mRNAs expression
following crush injuries. These may be due to the differ-
ent paradigms of injuries used. Crush but not cut injuries
enable regeneration and potential regulation of cytokine
mRNA expression by the growing axons.
Figure 3 The time course of cytokine protein secretion during
normal Wallerian degeneration. Nerve segments located 5
millimeters distal to lesion sites were removed from wild-type mice
at the indicated times and used to condition medium with secreted
cytokine proteins that were detected and quantified by ELISA.
Values are presented as percentage of maximum secretion which is
defined 100% (after [60,86]). The secretion of IL-1a is detected
within 6 hours after the injury; not shown here since the method of
detection was by a bioassay [87].
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cytokine proteins during the first and second phases of
normal Wallerian degeneration; i.e. before and after
macrophage recruitment. The first phase is characterized
by the production of the inflammatory cytokines TNFa,
IL-1a,I L 1 - b,G M - C S Fa n dI L - 6 .T h es e c o n dp h a s ei s
characterized by the production of IL-10, IL-6, and a
GM-CSF inhibitor molecule, and furthermore, by the
reduced production of TNFa and IL1-b.T h e r e f o r e ,t h e
first phase is mostly inflammatory and the second is pre-
dominantly anti-inflammatory. Further, it is very likely
that recruited macrophages are of the M2 phenotype
which is involved in tissue repair (Appendix 3), since
they produce high levels of IL-10 and IL-6, less TNFa
and IL1-b, and little if any GM-CSF. Apolipoprotein-E
[89,90] and Galectin-3/MAC-2 [91] can both direct the
polarization of recruited macrophages towards the M2
phenotype. Apolipoprotein-E is produced and secreted
by resident fibroblasts during normal Wallerian degen-
eration as of day 2 and later on also by macrophages
[92,93] as is Galectin-3/MAC-2 (see above). Of note,
both apolipoprotein-E and Galectin-3/MAC-2 are pro-
duced in Wld
s mice at injury sites but not during slow
Wallerian degeneration.
A deficient cytokine network develops during slow
Wallerian degeneration in Wld
s mice since the production
of cytokine proteins is dramatically lower during slow
Wallerian degeneration than it is during normal Wallerian
degeneration even though the expression of cytokine
mRNAs is upregulated [60,63,82,86]. In contrast, cytokine
mRNAs are expressed and proteins produced in injured
Wld
s PNS nerves at lesion sites concomitant with
Figure 4 The cytokine network of Wallerian degeneration. Injury sets in motion the cytokine network of normal Wallerian degeneration.
Intact myelinating Schwann cells enwrap intact axons and further express normally the inflammatory cytokines TNFa and IL-1a mRNAs and the
TNFa protein. Traumatic injury at a distant site in the far left (not shown) induces the rapid upregulation of TNFa and IL-1a mRNAs expression
and proteins production and secretion by Schwann cells within 5 hours. The nature of the signal(s) that are initiated at the injury site, travel
down the axon, and then cross over to Schwann cells are not known (?). Concomitantly, Schwann cell derived TNFa and IL-1a induce resident
fibroblasts to upregulate the expression of cytokines IL-6 and GM-CSF mRNAs and the production and secretion of their proteins within 2 to 5
hours after the injury. Inflammatory IL-1b mRNA expression and protein production and secretion are induced in Schwann cells with a delay of
several hours. The expression of chemokines MCP-1/CCL2 and MIP-1a/CCL3 are upregulated by TNFa, IL-1b and IL-6 as of day 1 after the injury
in Schwann cells, and possibly also in fibroblasts and endothelial cells. In turn, circulating monocytes begin their transmigration into the nerve
tissue 2 to 3 days after the injury. Fibroblasts begin producing apolipoprotein-E (apo-E) and Schwann cells Galectin-3/MAC-2 (Gal-3) just before
the onset of monocyte recruitment. Apolipoprotein-E and Galectin-3/MAC-2 may drive monocyte differentiation towards M2 phenotype
macrophage which further produces apolipoprotein-E and Galectin-3/MAC-2. Macrophages efficiently produce IL-10 and IL-6 and much less
TNFa, IL-1a, IL-1b. The anti-inflammatory cytokine IL-10, aided by IL-6, down-regulates productions of cytokines. Schwann cells and fibroblasts
produce also LIF. Arrows indicate activation and broken lines down-regulation. Not all possible interactions and molecules produced are shown
(e.g. autocrine interactions and the role of GM-CSF inhibitor); see text for additional information. The break-down of axons and myelin, and their
phagocytosis are not illustrated here; see, however, Figure 1 and Figure 2.
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myelin. The development of an efficient cytokine network
during normal Wallerian degeneration versus a deficient
cytokine network during slow Wallerian degeneration,
along with other aspects of innate-immunity (e.g. macro-
phage recruitment and phagocytosis of degenerated mye-
lin), highlight the inflammatory nature of normal
Wallerian degeneration.
The observation that cytokine proteins are not produced
during slow Wallerian degeneration even though the
expression of their mRNAs is upregulated [63], suggests
that cytokines mRNAs and proteins are differentially regu-
lated during Wallerian degeneration, and furthermore,
that mRNA expression does not necessarily indicate that
the respective protein is produced. Therefore, it is useful
to study both cytokine protein production and secretion
along with cytokine mRNA expression.
Chemokines, recruitment of macrophages and Wallerian
degeneration
Chemokine MCP-1 (chemoattractant protein-1; known
also as CCL2, C-C motif ligand 2) and MIP-1a (macro-
phage inflammatory protein-1a; known also as CCL3)
promote the transmigration of monocytes across the
endothelial cell wall of blood vessels (Figure 4). MCP-1/
CCL2, which Schwann cells produce, is upregulated
within hours after the impact at injury sites, and after 1
day at distal domains during normal Wallerian degen-
eration [6,61,62,66-68,94]. MCP-1/CCL2 production is
induced by TNFa and IL-1b, which Schwann cells
synthesize (see above), partly by signaling through TLRs
(toll-like receptors). In Wld
s mice, MCP-1/CCL2 is pro-
duced at injury sites, but not further distal where slow
Wallerian degeneration develops. Therefore, the occur-
rence and timing of MCP-1/CCL2 production are in
accord with those of TNFa and IL-1b that induce them.
These events further correlate with the occurrence and
timing of macrophage recruitment that MCP-1/CCL2
promotes. Studies in non-neuronal tissues suggest the
involvement of IL-6-dependent MCP-1/CCL2 produc-
tion by fibroblasts [95], and TNFa and IL1-b-dependent
production by endothelial cells [96]. Macrophage
recruitment is also promoted by MIP-1a/CCL3 [68].
Studies in Schwann cell tumors and non-neural tissues
suggest that Schwann cells, fibroblasts, endothelial cells
and macrophages may produce MIP-1a/CCL3 upon
activation by TNFa,I L - 1 a and IL-1b [96-98]. Recruit-
ment is further aided by TNFa-dependent induction of
MMP-9 (matrix metalloproteinase-9) that Schwann cells
produce [69-72] and by complement [73-75].
Immune inhibitory receptors and Wallerian degeneration
Innate-immune functions are regulated by the interplay
and balance between activating and inhibitory signals;
neither acts in an “all or none” fashion. Inhibition may
be produced by a family of immune inhibitory receptors.
SIRPa (signal-regulatory-protein-a;k n o w na l s oa s
CD172a and SHPS1) is a member of this family
[99-102]. SIRPa is expressed on myeloid cells (e.g.
macrophages and microglia) and some neurons, and is
activated by its ligand CD47 (known also as IAP - integ-
rin associated protein). CD47 is a cell membrane protein
receptor that various cells express (e.g. red blood cells,
platelets and some neurons). Cells that express CD47
down-regulate their own phagocytosis by macrophages
after CD47 binds to SIRPa on phagocytes. CD47 func-
tions, therefore, as a marker of “self” that protects cells
from activated autologous macrophages by sending a
“do not eat me” signal.
CD47 is expressed on myelin and the myelin-forming
Schwann cells and oligodendrocytes, and furthermore,
myelin down-regulates its own phagocytosis by macro-
phages and microglia through SIRPa-CD47 interactions
[85]. CD47 may function, therefore, as a marker of “self”
that protects intact myelin, Schwann cells and oligoden-
drocytes from activated macrophages in PNS and activated
microglia and macrophages in CNS. This mechanism may
be useful under normal conditions and while combating
invading pathogens since it protects bystander intact mye-
lin and myelin-forming cells from macrophages and
microglia that are activated to scavenge and kill pathogens.
However, the very same mechanism may turn harmful
when faster removal of degenerating myelin is useful; e.g.
as after traumatic axonal injury [7-10] (see above also).
Therefore, normal Wallerian degeneration does not dis-
play the fastest possible rate of in-vivo myelin clearance.
Neurotrophic factors and Wallerian degeneration
Peripheral nerve injury induces the production of neuro-
trophic factors by Schwann cells and fibroblasts during
normal Wallerian degeneration. Neurotrophic factors are
peptides that regulate, amongst others, neuronal survival,
axon growth and synapse formation during normal devel-
opment and during adulthood after traumatic PNS nerve
injury and other neuropathologies. They exert their effects
on axons after binding to their cognate receptors at nerve
endings and/or after being transported retrogradely to
neuronal cell bodies. This review is not aimed at discuss-
ing neurotrophic factors in detail. Nonetheless, nerve
injury induced production of NGF (nerve growth factor),
IL-6 and LIF (leukemia inhibitory factor) will briefly be
reviewed to highlight how the innate-immune properties
of normal Wallerian degeneration may regulate neuro-
trophic functions.
Among families of neurotrophic factors is the neuro-
trophin family. It consists of NGF, BDNF (brain derived
neurotrophic factor), NT (neurotrophin)-3, and NT-4/5;
their functions and mechanisms of action have been
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duction of NGF, BDNF and NT-4 is upregulated during
normal Wallerian degeneration [108-113]. Among these,
NGF promotes neuronal survival and axon growth of
sympathetic and subsets of sensory dorsal root neurons.
Since these neurons send their axons through PNS
nerves, they can interact with NGF that is produced
during normal Wallerian degeneration as they regener-
ate. NGF mRNA expression is upregulated in two
phases at the injury site and further distal to it; the first
peaks within hours and the second 2 to 3 days after the
injury. IL-1a,I L - 1 b and TNFa contribute to NGF
mRNA upregulation in fibroblasts but not in Schwann
cells. Of note, NGF mRNA and protein upregulations
c o r r e l a t eo n l yp a r t l ys i n c eo n l yt h es e c o n dp h a s eo f
mRNA expression is coupled with a corresponding
upregulation in NGF protein production [108]. The
upregulation NGF mRNA expression is prolonged after
cut injuries but transient after crush injuries, suggesting
that axons that regenerate after crush down-regulate
NGF expression [110]. Further, the upregulation of NGF
mRNA expression is impeded during slow Wallerian
degeneration in Wld
s mice [42] as are IL-1b and TNFa
protein productions [63].
IL-6 is a member of the IL-6 family that includes
amongst others LIF and CNTF (ciliary neurotrophic fac-
tor) [104,114,115]. The production of IL-6 and LIF is
upregulated during normal Wallerian degeneration; IL-6
by resident fibroblasts and recruited macrophages [63,86],
and LIF by resident Schwann cells and fibroblasts
[116,117]. Apart from being modulators of innate-immune
functions, IL-6 [118-120] and LIF [121,122] also display
neurotrophic properties by promoting neuronal survival
and axon growth. Further, LIF may also function as a
Schwann cell growth factor [123].
Neuropathic pain and Wallerian degeneration
The innate-immune response of injury-induced Waller-
ian degeneration may also produce neuropathic pain; i.e.
the development of spontaneous pain and/or painful sen-
sation to innocuous stimuli. This review is not aimed at
discussing neuropathic pain in detail, but to highlight its
relationship to injury-induced Wallerian degeneration. In
general, neuropathic pain develops in association with
various pathologies through diverse mechanisms; recently
reviewed in [124-126]. One class of mechanisms relates
to the innate-immune properties of Wallerian degenera-
tion as revealed by the observations that injury-induced
neuropathic pain is delayed and reduced in Wld
s mice
[127] and also in IL-6 deficient mice [128]. Further, neu-
ropathic pain (also referred to as inflammatory pain) can
be evoked by inflammation without injury [129-135].
IL-1b,T N F a, and NGF, which are produced during nor-
mal Wallerian degeneration, have been implicated. IL-1b
and TNFa may sensitize intact axons to produce sponta-
neous activity and/or enhanced activity in response to
mechanical and thermal stimuli. IL-1b and TNFa further
induce the expression of NGF, which, in turn, sensitizes
sensory nerve endings. This is mostly evident after partial
PNS nerve injury where some but not all axons are trau-
matized (Figure 1; imagine that axon A is situated next to
axon E). Therefore, delayed and reduced neuropathic
pain in Wld
s mice may be explained, at least in part, by
reduced productions of IL-6, IL-1b, TNFa, and NGF.
Putting it altogether - orchestration is important
Successful functional recovery by regeneration is pro-
moted by the removal of inhibitory degenerated myelin
and production of neurotrophic factors. Innate-immune
mechanisms that develop during normal Wallerian degen-
eration regulate both. Those, in turn, depend on the
orchestrated interplay between Schwann cells, fibroblasts,
macrophages, and endothelial cells and molecules they
produce (Figure 4).
Intact Schwann cells are best suited amongst non-neu-
ronal cells to “sense” and rapidly respond to the axotomy
at remote sites by rapidly upregulating the expression and
production of TNFa and IL-1a first, and IL-1b thereafter.
This is made possible since Schwann cells form intimate
contacts with axons, molecular machineries by which
axons and Schwann cells communicate signals exists (e.g.
neuregulin-Erb interactions), and intact Schwann cells
further normally express TNFa and IL-1a, which enables
their fast upregulation.
Schwann cell-derived TNFa,I L - 1 a and IL-1b induce
adjacent resident fibroblasts to produce IL-6, GM-CSF
and LIF within few hours after injury. Thereafter, TNFa,
IL-1a,I L - 1 b and IL-6 induce the production of MCP-1/
CCL2 and MIP1-a/CCL3 in Schwann cells, fibroblasts and
endothelial cells. The two chemokines promote the trans-
migration of bone-marrow monocytes across structurally
intact walls of blood vessels into the PNS nerve tissue.
Consequently, the recruitment of monocytes begins 2 to 3
days after the injury, reaching highest numbers at about 7
days. Apolipoprotein-E and Galectin-3/MAC-2 that are
produced before and during monocyte recruitment may
help drive monocyte differentiation towards the M2 phe-
notype tissue macrophage.
Schwann cells and axons display minor structural
changes 12 and 24 hours after the injury and profound
disintegration 2 to 3 days after the injury. They then
become amenable for scavenging by activated Galectin-3/
MAC-2 expressing macrophages and Schwann cells; the
onset of clearance is 3 to 4 days after the injury and com-
pletion is after 12 to 14 days. Indeed, there is a remarkable
matching between setting-up the machinery for scaven-
ging the degenerated myelin and its actual removal.
Setting-up begins with the recruitment of macrophages
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express Galectin-3/MAC-2 by fibroblast-derived GM-CSF
before the onset of myelin clearance; most of the degener-
ated myelin is removed when activated Galectin-3/MAC-
2
+ macrophages and Schwann cells reach highest
numbers; activation (Galectin-3/MAC-2 expression) is
down-regulated after degenerated myelin is removed.
Bringing the innate-immune response to conclusion is
aided by the production of the anti-inflammatory cytokine
IL-10 which TNFa,I L - 1 a and IL-1b induce in the
recruited M2 phenotype macrophages. Effective IL-10
levels are reached 7 days after the injury when macro-
phage recruitment peaks. Then, IL-10 gradually down-
regulates the production of cytokines; reaching lowest
levels in about 2 to 3 weeks after injury, thus well after
degenerated myelin is cleared. The GM-CSF inhibitor
molecule and IL-6, due to its anti-inflammatory properties,
help to down-regulate the production and activity of
cytokines.
Wallerian degeneration further upregulates neurotrophic
properties. The production of NGF is rapidly induced after
the injury in Schwann cells and fibroblasts; in the latter by
TNFa,I L - 1 a and IL-1b. Further, IL-6 and LIF function as
neurotrophic factors as well as classical cytokines. There-
fore, the development of some neurotrophic properties is
tightly associated with the development of the innate-
immune properties of normal Wallerian degeneration.
The failure to develop an efficient innate-immune
response in slow Wallerian degeneration supports the
view that innate-immunity plays critical roles in normal
Wallerian degeneration and the restoration of function
t h a tf o l l o w s .T h ei n n a t e - i m m u n er e s p o n s eo fn o r m a l
Wallerian degeneration depends on upregulating the pro-
duction of TNFa and IL-1a proteins in Schwann cells.
However, the production of these cytokine proteins is not
upregulated during slow Wallerian degeneration even
though the expression of their mRNAs is induced. In
accord with the notion that TNFa and IL-1a proteins
help putting the innate-immune properties of normal
Wallerian degeneration in motion, the failure to upregu-
late their protein production during slow Wallerian degen-
eration impedes dramatically the development of an
efficient innate-immune response, NGF production, and
repair.
Conclusion
Innate-immunity is central to injury-induced PNS
Wallerian degeneration since innate-immune cells,
functions and molecules are involved. Repair depends
on an efficient innate-immune response that helps
turning the PNS tissue into an environment that sup-
ports axon regeneration by removing inhibitory myelin
and by upregulating neurotrophic properties. Recovery
is poor when innate-immune mechanisms fail to
develop. Therefore, the innate-immune mechanisms of
Wallerian degeneration may be targeted to ensure
successful functional recovery from trauma.
Appendices
Appendix 1: Galectin-3/MAC-2 activates myelin
phagocytosis by macrophages and further promotes
Schwann cells to scavenge myelin
Galectin-3, formally named MAC-2 [136], is a multifunc-
tional b-galactoside binding protein and a member of the
Galectin family of lectins; reviewed recently in [137-139]. It
is present in the nucleus and cytoplasm of many cells, and
it may also be secreted. Cytosolic Galectin-3/MAC-2 acti-
vates myelin phagocytosis in macrophages and microglia.
Myelin phagocytosis by CR3 and SRA involves signaling
through phosphatidylinositol 3-kinase (PI3K) [140,141].
PI3K is preferentially activated by K-Ras.GTP which Galec-
tin-3/MAC-2 binds and stabilizes [137,142]. As a result,
Galectin-3/MAC-2 enhances K-Ras.GTP-dependent func-
tions. K-Ras.GTP/PI3K-dependent phagocytosis of degen-
erated myelin is similarly activated by Galectin-3/MAC-2
[143,144].
The molecular mechanisms that enable Schwann cells to
scavenge their own degenerated myelin are unclear as
Schwann cells do not express CR3, SRA or FcgR that med-
iate myelin phagocytosis in macrophages and microglia.
However, Galectin-3/MAC-2 may be involved [16]. Intact
myelinating Schwann cells do not express detectable levels
of Galectin-3/MAC-2, but they do so as they internalize
degenerated myelin in-vivo during normal Wallerian
degeneration and in-vitro during in-vitro Wallerian degen-
eration; i.e. when intact nerves are moved to culture and
so degenerate in the absence of recruited macrophages.
Further, galactose and lactose, which inhibit binding to
Galectin-3/MAC-2, impede the disintegration and interna-
lization of myelin by Schwann cells. Therefore, secreted
Galectin-3/MAC-2 is likely involved.
Appendix 2: Cytokines are multi functional proteins
Cytokines are small proteins that regulate innate-immune
functions in immune cells (e.g. phagocytosis and produc-
tion of cytokines by macrophages). However, some cyto-
kines further modulate immune and non-immune
functions in non-immune cells (e.g. production of cyto-
kines and nerve growth factor in fibroblasts), and others
(e.g. IL-6 and LIF) also display neurotrophic properties
(see text). Therefore, many cytokines are indeed multi-
functional. While most cytokines function after being
released from the producing cells, others may also func-
tion membrane-bound (e.g. TNFa). Further, cytokines
may be divided into major classes. Inflammatory cytokines
(e.g. TNFa,I L - 1 a,a n dI L - 1 b; also referred to as pro-
inflammatory) promote the production of inflammatory
mediators, and anti-inflammatory cytokines (e.g. IL-10)
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Nonetheless, some cytokines (e.g. IL-6) display both
inflammatory and anti-inflammatory properties [145]; see
also review [146].
Appendix 3: Tissue macrophages can differentiate into
M1 and M2 phenotypes
M1 and M2 phenotypes are two extremes of a spectrum.
The M1 phenotype is considered inflammatory since,
amongst others, it produces the inflammatory cytokines
TNFa,I L - 1 a and IL-1b, and is involved in killing patho-
gens. The M2 phenotype is considered anti-inflammatory
since, amongst others, it produces the anti-inflammatory
cytokine IL-10, it does not produce inflammatory cyto-
kines or very little, and is involved in tissue remodeling
and wound-healing. Both M1 and M2 phenotype macro-
phages produce IL-6, which is both inflammatory and
anti-inflammatory in nature, and further function as pha-
gocytes; reviewed in [147-152].
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